We are live on ! Find out more

State Street SPDR S&P Pharmaceuticals ETF

XPH

Market cap $456M

65.18 USD

+0.63

0.98%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

65.28

+0.10

0.15%

1 day

0.98%

5 days

1.88%

1 month

-1.38%

3 months

-5.12%

6 months

15.28%

Year to date

18.06%

1 year

34.25%

5 years

35.9%

10 years

63.97%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 6.7%

Neutral 66.7%

Negative 26.7%

The Motley Fool

Which Healthcare ETF Is the Better Buy: State Street's Pharma XPH or Simplify's Mission-Driven PINK?

State Street SPDR S&P Pharmaceuticals ETF offers a lower expense ratio but has a lower dividend yield than Simplify Health Care ETF. Simplify Health Care ETF has shown significantly lower maximum drawdowns than the SPDR fund over the last five years.

Which Healthcare ETF Is the Better Buy: State Street's Pharma XPH or Simplify's Mission-Driven PINK?

Zacks Investment Research

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

XPH: Healthcare Sector Dashboard For October

Pharmaceuticals/biotechnology are currently overvalued by 14% versus 11-year averages, while healthcare equipment appears undervalued despite recent value score deterioration. State Street SPDR S&P Pharmaceuticals ETF offers diversified pharma exposure with low company-specific risk due to its modified equal-weight methodology. XPH is best suited for tactical allocation or swing trading, not as a compelling long-term holding, given its historical risk-return profile and sector dynamics.

XPH: Healthcare Sector Dashboard For October

The Motley Fool

Better Pharma ETF: iShares IHE vs. State Street XPH

The iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio. The iShares U.S. Pharmaceuticals ETF provides a higher dividend yield of 1.4% compared to 0.4% for the State Street SPDR S&P Pharmaceuticals ETF.

Better Pharma ETF: iShares IHE vs. State Street XPH

The Motley Fool

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma

The VanEck Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF both carry an identical expense ratio of 0.35%. The State Street SPDR S&P Pharmaceuticals ETF is more diversified with 62 holdings, while the VanEck Biotech ETF focuses on 25 holdings.

Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma

Zacks Investment Research

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund launched on June 19, 2006.

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

Zacks Investment Research

Execution of Pharma Tariffs Brings These ETFs Into Focus

Trump's 100% pharma tariff is reshaping the drug industry. Here's how the key pharma ETFs could be affected.

Execution of Pharma Tariffs Brings These ETFs Into Focus

The Motley Fool

IXJ vs XPH: Global Healthcare ETF or Pharma Focus?

iShares Global Healthcare ETF provides broad sector coverage with a higher dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered stronger total returns over the last year but experiences significantly higher maximum drawdowns.

IXJ vs XPH: Global Healthcare ETF or Pharma Focus?

The Motley Fool

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

The Vanguard Health Care ETF offers a significantly lower expense ratio and a higher dividend yield than the State Street SPDR S&P Pharmaceuticals ETF. The State Street SPDR S&P Pharmaceuticals ETF provides concentrated exposure to drug manufacturers, while the Vanguard Health Care ETF covers a broader range of medical services and equipment.

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

The Motley Fool

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?

Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.35% charged by State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF focuses specifically on the pharmaceutical industry, whereas Fidelity MSCI Health Care Index ETF tracks the broader healthcare sector.

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?

See News Rankings

Price charts implemented using Lightweight Charts™